BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 15837743)

  • 1. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR and erbB2 mutation status in Japanese lung cancer patients.
    Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
    Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR polymorphism of the kinase domain in Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Tanaka H; Kitahara N; Matsumura A; Iuchi K; Kawaguchi T; Okuda K; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    J Surg Res; 2008 Aug; 148(2):260-3. PubMed ID: 18541260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
    Takano T; Ohe Y; Sakamoto H; Tsuta K; Matsuno Y; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Shibata T; Sakiyama T; Yoshida T; Tamura T
    J Clin Oncol; 2005 Oct; 23(28):6829-37. PubMed ID: 15998907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
    Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N
    Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
    Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
    Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
    Endo K; Sasaki H; Yano M; Kobayashi Y; Yukiue H; Haneda H; Suzuki E; Kawano O; Fujii Y
    Oncol Rep; 2006 Sep; 16(3):533-41. PubMed ID: 16865253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
    Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
    Endo K; Konishi A; Sasaki H; Takada M; Tanaka H; Okumura M; Kawahara M; Sugiura H; Kuwabara Y; Fukai I; Matsumura A; Yano M; Kobayashi Y; Mizuno K; Haneda H; Suzuki E; Iuchi K; Fujii Y
    Lung Cancer; 2005 Dec; 50(3):375-84. PubMed ID: 16199108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.
    Hata A; Yoshioka H; Fujita S; Kunimasa K; Kaji R; Imai Y; Tomii K; Iwasaku M; Nishiyama A; Ishida T; Katakami N
    J Thorac Oncol; 2010 Oct; 5(10):1524-8. PubMed ID: 20808254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
    Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
    Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
    Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
    Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC
    Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.